Zymo Research Granted CE IVD Mark for Quick SARS-CoV-2 rRT-PCR Kit

IRVINE, Calif., (Aug. 19, 2020) — Zymo Research announced that it was recently granted the CE IVD Mark for its Quick SARS-CoV-2 rRT-PCR Kit. To obtain this certification the product had to comply with the Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. The Quick SARS-CoV-2 rRT-PCR Kit is... Read more

FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older

Basel, 10 August 2020 In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA Evrysdi helped infants survive without permanent ventilation and achieve the ability to sit without support, a key motor milestone not... Read more

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer

Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-free survival (PFS) for the initial (first-line) treatment of people with metastatic... Read more

The United States Court of Appeals for the Federal Circuit Affirms that 10x Genomics Willfully Infringed Bio-Rad U.S. Patent and Upholds Lower Court’s Award of Damages

HERCULES, Calif. –Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that the The United States Court of Appeals for the Federal Circuit today affirmed that 10x Genomics willfully infringed U.S. Patent 8,889,083, exclusively licensed to Bio-Rad from the University of Chicago. The Appeals Court upheld... Read more

Brooks to Participate in the Needham Virtual SemiCap and EDA Investor Conference

CHELMSFORD, Mass., Aug. 4, 2020 /PRNewswire/ — Brooks Automation, Inc. (Nasdaq:BRKS) announced today that company management will participate in the Needham Virtual SemiCap and Electronic Design Automation Conference on Thursday, August 13, 2020 at 9:30 a.m. ET.  The 40-minute session will be webcast live via the Brooks investor relations website at www.brooks.investorroom.com/events. About Brooks AutomationBrooks... Read more

Thermo Fisher Scientific and Lyell Immunopharma Form Cell Therapy Manufacturing Partnership

Thermo Fisher Scientific and Lyell Immunopharma Form Cell Therapy Manufacturing Partnership Collaboration will include development of Thermo Fisher products and strategic manufacturing support WALTHAM, Mass., July 28, 2020 /PRNewswire/ — Thermo Fisher Scientific Inc., the world leader in serving science, and biotechnology company Lyell Immunopharma, are partnering to develop manufacturing processes designed to create more... Read more

Promega Maxwell® RNA Extraction System Authorized for Use in CDC COVID-19 Emergency Use Authorization (EUA) Diagnostic Panel

Promega automated sample preparation solution added to CDC COVID-19 test protocol Madison, WI USA. (July 16, 2020) Promega Corporation Maxwell® RSC 48 Instrument and Maxwell® RSC Viral Total Nucleic Acid Purification Kit (Maxwell® Extraction System) are now in the Centers for Disease Control and Prevention’s (CDC) COVID-19 diagnostic protocol for emergency use. In a letter dated July... Read more

Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints

      ·Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone alone) plus placebo met its co-primary endpoint of radiographic progression free survival (rPFS) in patients with PTEN loss tumours Basel, 19 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III... Read more

Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer

IMpassion031 data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency Tecentriq is the only approved cancer immunotherapy for the treatment of metastatic triple-negative breast cancer, a very aggressive and difficult-to-treat form of breast cancer Basel, 18 June 2020 – Roche (SIX: RO, ROG; OTCQX:... Read more

Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA)

Basel, 12 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented two-year data from Part 1 of its pivotal SUNFISH trial in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA) at the virtual Cure SMA Annual Conference, 8-12 June, 2020. The results of an exploratory efficacy analysis show... Read more